The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...

Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, ...

The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Under medical supervision, GLP-1 agonists often lead to safe, sustainable weight loss, as noted in clinical reviews ... for a full list of side effects. Zepbound is a GLP-1 agonist containing ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...